Latest AN2 Therapeutics News & Updates

See the latest news and media coverage for AN2 Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

AN2 Therapeutics

Clinical-stage biopharmaceutical company developing boron-based medicines

an2therapeutics.com

Headquarters: Menlo Park, United States
Founded year: 2019
Company type: Public company
Number of employees: 38–50
Industry: Pharmaceuticals

Last updated August 11

Latest news about AN2 Therapeutics

In short: AN2 Therapeutics advanced epetraborole into Phase 2 for polycythemia vera and reported positive Chagas data.

Company announcements

August 11 AN2 Therapeutics

AN2 Therapeutics reports Q2 2026 results

Highlights include epetraborole trial expansion and positive pharmacokinetics. The company also reported financial outcomes for the second quarter of 2026.

August 4 AN2 Therapeutics

AN2 Therapeutics advances epetraborole for NTM

The company highlights a Phase 2 trial for M. abscessus lung disease, noting the lack of FDA-approved therapies and honoring patient resilience.

June 4 AN2 Therapeutics

AN2 Therapeutics advances oral AN2-502998 to Phase 2 study for Chagas disease

Positive enabling data and favorable safety profile support the transition. Parasite elimination was achieved in nonhuman primates using a 28-day treatment regimen.

March 31 AN2 Therapeutics

AN2 Therapeutics initiates Phase 2 trial of epetraborole for lung disease

The investigator-initiated trial targets Mycobacterium abscessus complex infections using the company's boron chemistry platform.

Media coverage

June 4 Seeking Alpha

AN2 rises after early-stage trial data for Chagas disease therapy

AN2 Therapeutics (ANTX) added ~7% in the premarket on Thursday after posting results from two early-stage studies evaluating AN2-502998, its experimental therapy for a parasitic...

March 8 Pulse 2.0

AN2 Therapeutics: $40 Million Private Placement Financing Announced

AN2 Therapeutics announced that it has entered into a securities purchase agreement for a private placement expected to generate approximately $40 million in gross proceeds...

March 3 Nasdaq

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today...

November 10, 2025 Morningstar

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

Funding from Gates Foundation supports continued advancement of boron-based LeuRS inhibitors for the treatment of tuberculosis AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical...

Never miss news about AN2 Therapeutics

Track AN2 Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

AN2 Therapeutics competitors & trending companies

Browse news for competitors to AN2 Therapeutics and other trending companies.